

Romosozumab increases bone mineral density post-menopause

6 January 2014



Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the *New England Journal of Medicine*.

(HealthDay)—Romosozumab seems safe and effective for increasing bone mineral density in postmenopausal women with low bone mineral density, according to a study published online Jan. 1 in the *New England Journal of Medicine*.

Michael R. McClung, M.D., from the Oregon Osteoporosis Center in Portland, and colleagues conducted a phase 2 study to examine the efficacy and safety of romosozumab over a 12-month period in 419 [postmenopausal women](#), aged 55 to 85 years of age, with low [bone mineral](#) density. Participants were randomized to receive subcutaneous romosozumab every month (70, 140, or 210 mg) or every three months (140 or 210 mg), placebo, or an active comparator (70 mg weekly alendronate or 20 µg daily teriparatide).

The authors identified significant increases in bone mineral density at the lumbar spine with all dose levels of romosozumab, including a 11.3 percent increase with the 210-mg monthly dose, compared with a 0.1 percent decrease with placebo and 4.1 and 7.1 percent increases with alendronate and teriparatide, respectively. Large increases in bone mineral density were seen at the total hip and femoral neck, as well as transitory increases in [bone-formation](#) markers with romosozumab, while sustained decreases were observed in a [bone-](#)

[resorption](#) marker. Adverse events were similar between the groups, except for mild, generally nonrecurring injection-site reactions with romosozumab.

"Romosozumab was associated with increased [bone mineral density](#) and bone formation and with decreased bone resorption," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen and UCB Pharma, which funded the study.

More information: [Abstract](#)

[Full Text](#)

[Editorial](#)

Copyright © 2014 [HealthDay](#). All rights reserved.

APA citation: Romosozumab increases bone mineral density post-menopause (2014, January 6)
retrieved 9 August 2022 from <https://medicalxpress.com/news/2014-01-romosozumab-bone-mineral-density-post-menopause.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.